Current scenario of pyrazole hybrids with anti‐breast cancer therapeutic applications
Archiv der Pharmazie · 2024
DOI: 10.1002/ardp.202400344 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Archiv der Pharmazie, 2024. Verfasst von Mengyu Ma. Beteiligte Einrichtung: Department of Pharmaceutical Engineering, School of Chemistry and Pharmaceutical Engineering, Huanghuai University, Zhumadian, Henan, People's Republ…. Hauptthemen laut MEDLINE: Pyrazoles, Breast Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 97 Literaturangaben. Gefördert von: Programs for Science and Technology Innovation Youth Special Project of Zhumadian.
Abstract (Originalsprache)
Breast cancer stands as the leading cause of cancer‐related deaths among women globally, but current therapy is restricted to the serious adverse effects and multidrug resistance, necessitating the exploration of novel, safe, and efficient anti‐breast cancer chemotherapeutic agents. Pyrazoles exhibit excellent potential for utilization as effective anti‐breast cancer agents due to their ability to act on various biological targets. Particularly, pyrazole hybrids demonstrated the advantage of targeting multiple pathways, and some of them, which are exemplified by larotrectinib (pyrazolo[1,5‐ a ]pyrimidine hybrid), can be applied for breast cancer therapy. Thus, pyrazole hybrids hold great promise as useful therapeutic interventions for breast cancer. The aim of this review is to summarize the current scenario of pyrazole hybrids with in vitro and/or in vivo anti‐breast cancer potential, along with the modes of action and structure–activity relationships, covering articles published from 2020 to the present, to streamline the development of rational, effective and safe anti‐breast cancer candidates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Engineering, School of Chemistry and Pharmaceutical Engineering, Huanghuai University, Zhumadian, Henan, People's Republic of China.
Förderung
- Programs for Science and Technology Innovation Youth Special Project of Zhumadian
Zitieren
APA
Ma, M. (2024). Current scenario of pyrazole hybrids with anti‐breast cancer therapeutic applications. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202400344
Vancouver
Ma M. Current scenario of pyrazole hybrids with anti‐breast cancer therapeutic applications. Archiv der Pharmazie. 2024. doi:10.1002/ardp.202400344
BibTeX
@article{Ma2024,
author = {Ma, Mengyu},
title = {Current scenario of pyrazole hybrids with anti‐breast cancer therapeutic applications},
journal = {Archiv der Pharmazie},
year = {2024},
doi = {10.1002/ardp.202400344}
}
EUVIMED